The IND clearance is a positive regulatory step but does not guarantee clinical success. Monitor patient enrollment and interim Phase 2 data for GT-02287, which are the next key catalysts. The 91% analyst bullish consensus already reflects optimism, so the stock may have limited upside near-term without further data.
Price Chart
Executive Summary
Gain Therapeutics announced FDA authorization of its IND application for GT-02287, allowing Phase 2 clinical development in Parkinson's disease in the U.S. The Phase 1 studies showed favorable safety, tolerability, and biomarker activity, supporting advancement. This milestone de-risks the program modestly but Phase 2 data is still pending.
Key Facts
- FDA authorized IND for GT-02287, enabling Phase 2 initiation in the U.S. during 3Q26.
- Phase 1 results demonstrated target engagement, biomarker reduction (81% reduction in CSF GluSph at Day 90), and favorable safety/tolerability.
- Phase 2a will enroll early Parkinson's patients across U.S., Australia, and Europe.
- GT-02287 is an allosteric GCase modulator targeting the underlying biology of Parkinson's disease.
Financial Impact
No financial data disclosed; milestone may positively affect valuation but limited near-term revenue impact.
Risk Factors
- Phase 2 trial may fail to replicate Phase 1 efficacy or safety results.
- Competitive landscape includes other disease-modifying therapies for Parkinson's.
- Company has no approved products and relies on financing for operations.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3319285 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 1, 2026 26d ago | Press Release | $1.72 $1.62 | ▼ −6.10% | ▼ −7.41% | $1.18 (−31.40%) |
Oct 1, 2026 26d ago | 8-K | $1.72 $1.62 | ▼ −6.10% | ▼ −7.41% | $1.18 (−31.40%) |
Aug 11, 2026 11w ago | Press Release | $2.06 $2.03 | ▼ −1.46% | ▼ −1.05% | $1.18 (−42.72%) |
Jul 16, 2026 14w ago | 8-K | $1.66 $1.82 | ▲ +9.64% | ▲ +11.31% | $1.18 (−28.92%) |
Jun 29, 2026 17w ago | 8-K | $2.03 $1.81 | ▼ −10.84% | ▼ −11.44% | $1.18 (−41.87%) |
Jun 29, 2026 17w ago | Press Release | $2.03 $1.81 | ▼ −10.84% | ▼ −11.44% | $1.18 (−41.87%) |
May 26, 2026 22w ago | 8-K | $1.82 $1.96 | ▲ +7.69% | ▲ +6.61% | $1.18 (−35.16%) |
May 11, 2026 24w ago | Press Release | $1.82 $1.62 | ▼ −10.99% | ▼ −10.90% | $1.18 (−35.16%) |
Apr 28, 2026 25w ago | DEFA14A | $1.76 $1.91 | ▲ +8.52% | ▲ +5.41% | $1.18 (−32.95%) |
Mar 26, 2026 30w ago | Press Release | $1.89 $1.85 | ▼ −2.12% | ▼ −3.75% | $1.18 (−37.57%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers